
Fundamental analysis: LadRx Corporation (CYTR)
Awarener score: could not be estimated
Conclusion
The higher the Awarener score, the more bang you get for the buck. It measures how much genuine funds the company generates for the stock price paid (could not be estimated), the business stability (unknown) and growth (unknown), and the company's inclination to return cash to the stockholders (unknown).
Note: All scores range from 1 (worst) to 10 (best). Conclusions are updated daily with closing stock prices and new reported quarterly financial statements.
Revenue score: a result could not be reached
- Business growth could not be estimated, due to not enough input data. It's been unavailable to compare with peer companies.
- LadRx Corporation business stability could not be estimated, due to insufficient input data. It looks we cannot compare it to rivals.
Margins score: 1.0
- CYTR profit margins -on goods and services sold- are usually destitute. They stand worse than most rival companies.
- Business profit on sales tends to be pauper. It's substantially worse when measured against competitors.
- Profits on sales made -available to repay debt and purchase properties- are usually destitute. They remain in a very weak position compared to peers.
- Earnings -before income taxes and interests on loans taken- tend to be pauper in relation to total revenues. They're still worse than most similar companies.
- Profits -before income taxes- are usually destitute considering total sales, and remain substantially worse when measured against rivals.
- Total net profit tends to be pauper when confronted to sales. Company stands substantially worse when measured against comparable firms.
Growth score: 1.0
- LadRx Corporation has an unknown gross margin growth, as there is not enough data to analyze. It's been impossible to compare to competitors.
- In recent years, the firm hasn't always been able to profit from operations, which has been bottom tier against comparable firms.
- In past years, the company couldn't always turn a profit -available to repay debt and purchase properties-, which compares last-in-rank when measured against peer enterprises.
- In the previous years, the firm couldn't always make a profit -before income taxes and interests on loans taken-. It turns to be a disappointment compared to similar stocks.
- In past years, at least once the company lost money -before income taxes-. It was bottom tier against rivals.
- In the previous years, the firm had at least a total net loss, and last-in-rank when measured against peer companies.
- The company lost money at least once in the past years. It's been a disappointment compared to industry peers.
Miscellaneous score: 1.7
- CYTR had still to pay income taxes, even though in recent past years mostly lost money. It's been bottom tier against peers.
- Research and development expenses consume a huge portion of revenues. It's weak when measured against competitors.
- The company hardly grows despite of research and development efforts. It stands lacking compared to rival companies.
Profitability score: 1.2
- LadRx Corporation usually gets pauper returns on the resources it controls. It proves below average when measured against peer firms.
- The company normally gets extremely poor proceeds -on the resources directly invested in the business-. They remain in a very weak position compared to similar companies.
- There's usually bottom profitability -in relation to owned resources-. It ranks last-in-rank when measured against competitors.
- In the past, got very poor returns -on the tangible resources it controls-. This metric is usually related to the industry in which operates and combines profitability versus reinvestment needs. It's below average when measured against comparable enterprises.
Usage of Funds score: 3.2
- CYTR on average doesn't generate genuine funds, so to buy or replace property, plants and equipment must either burn existing cash or increase debt. It stands below average when measured against rival firms.
- The company is usually not replacing property, plant, and equipment that gets old, instead using funds in something else. It can't keep forever, which is substantially worse when measured against industry peers.
- There was no available information regarding dividend yield. It came unknown against competitors.
- Has recently started or restarted paying dividends to stockholders. Business prospects are most likely good. The company has behaved impressive in relation to similar firms.
- The company generates very few genuine funds. Dividend payments are usually on borrowed money, which isn't sustainable in the long run. Unless business prospects improve greatly, future payments could be at risk. Sustainability looks bottom tier against comparable companies.
- The company usually significantly enlarges the pool of investors, resulting in more mouths feeding on the pie of profits. It remains excellent in relation to peer enterprises.
- Repurchase effectiveness metric is very complex. Run again in analytical mode if you're interested in a technical explanation. It stands in a very weak position compared to rivals.
- We do not have sufficient data to comment on buybacks and their sustainability. It still looks dubious against competitors.
Balance Sheet score: 6.0
- LadRx Corporation has no intangible assets (like brands and goodwill) according to accounting books, which is safest. It happens to be top tier when measured against peer companies.
- The company has roughly double short-term resources than short-term obligations. Liquidity concerns are normally not an issue. It turns to be in a very weak position compared to similar firms.
- Roughly a tenth of resources controlled were provided for with financial debt. Creditors have minor claims on the company, and financial position is safe. It remains slightly worse than rival firms.
- Most resources controlled are already cash or short-term investments, which is best for liquidity. It looks similar to rivals.
- For every dollar of short-term obligations, the company has more than enough dollars in cash and short-term receivables. It's in a very weak position compared to peer firms.
- For every dollar of short-term obligations, the company has enough dollars in cash and equivalents, which is worse than most similar enterprises.
- Days of sales outstanding are not known, out of lack of data. It still ranks unknown against peers.
- Days of inventory outstanding are not known. It comes up as a big question mark against competitors.
- We could not gauge the normal operating cycle of the company. It happens to be a mystery against peers.
- Unfortunately, we had not enough data to estimate the days of payables outstanding. It ranks unknown against industry peers.
- Cash conversion cycle remains unknown, due to not having enough inputs. It's incomparable against similar companies.
- Company earns net interest income on its investments and therefore is in a quite comfortable financial position. It stands top-notch against rival firms.
- Business has usually been operated at a loss. Unless prospects improve, the company is no position to decrease loans taken levels but by additional shareholders' funding. Profitability must improve. It ranks last-in-rank when measured against comparable enterprises.
- The company didn't have revenues in the past twelve months. It must start having income to take advantage of used resources. It looks in a very weak position compared to similar firms.
- The firm has yet to start reporting any sales. It's still worse than most peer companies.
Valuation score: 7.8
- LadRx Corporation reported losses, so valuating it in relation to earnings is meaningless. It happens to be last-in-rank when measured against competitors.
- Price-to-Tangible-Book-Value is a fairly complex metric. Run again in analytical mode if you're interested in a technical explanation. It remains impressive in relation to peers.
- There is insufficient information on the genuine funds generation capability showed in the past twelve months, which stands as an incognita in relation to similar companies.
- Unfortunately, lack of enough yearly data impaired our ability to estimate the normal earnings power. It's still an unknown variable to measure against industry firms.
- A conclusion regarding usual company rewards to stockholders was impossible to reach with data available. It came up also not enough to relate to peer ventures.
- We are unsure on the relationship between net financial position and market capitalization of the stock. It looks we will not be able to reach a conclusion regarding similar enterprises.
- Considering the past twelve months, traditional Price-to-Earnings relation looks extremely cheap. Possible reasons are that the market might be betting current earnings will be very hard to sustain through time, or that the company has very high fund needs, a weak financial position, or that earnings aren't representative. If that isn't the case, the stock price could be extremely attractive. It ranks top tier when measured against peer companies.
- Price-to-Sales ratio is currently an incognita. It looks incomparable with rival firms.
- The stock price is significantly below the accounting book value. Unless profitability is extremely low, the stock may be selling at a large discount. Pay attention to the other key indicators for hints. The company remains top-notch against peer firms.
- We could not gauge an alternative metric of earnings power of the past twelve months. It happens to be an interesting metric to relate to industry peers.
- An alternate metric on the usual genuine-funds generation ability could not be provided. It's still unknown against peer companies.
Total score: 3.1

Company at a glance: LadRx Corporation (CYTR)
Sector, industry: Healthcare, Biotechnology
Market Cap: unavailable
Revenues TTM: unavailable
LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.
Awarener score: could not be estimated
Conclusion
The higher the Awarener score, the more bang you get for the buck. It measures how much genuine funds the company generates for the stock price paid (could not be estimated), the business stability (unknown) and growth (unknown), and the company's inclination to return cash to the stockholders (unknown).